MedTrace Logo

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

NCT00633789 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 597

Last updated 2015-10-09

No results posted yet for this study

Summary

The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib

Conditions

Interventions

DRUG

brivanib

Tablets, Oral, 800 mg, once daily, until progression

DRUG

Placebo

Tablets, Oral, 0 mg, once daily, until progression

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-02-29
Completion
2012-12-31

Countries

  • United States
  • Argentina
  • Belgium
  • Canada
  • France
  • Germany
  • Netherlands
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00633789 on ClinicalTrials.gov